Clinical trial · Interventional
Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors
Application of 68Ga-NODAGA-SNA006 in Patients With Solid Tumor or Lymphoma
NCT07059832CI-TRIAL-00092006active not recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in subjects with solid tumor or lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-NODAGA-SNA006 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Feasibility and safety of 68Ga-NODAGA-SNA006
- description
- 68Ga-NODAGA-SNA006 0.05 mCi/Kg, interval time between FDG was within five days
- interventionNames
- Drug: 68Ga-NODAGA-SNA006
Primary outcomes (2)
- measure
- Incidence of 68Ga-NODAGA-SNA006-emergent Adverse Events
- timeFrame
- 3 YEAR
- description
- Through PET/CT, Visual analysis was positive, or the SUVmax was more than the mediastinum
- measure
- Biodistribution of 68Ga-NODAGA-SNA006
- timeFrame
- 3 YEAR
- description
- Through PET/CT analysis, SUVmax and SUVmean of the organs
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Participants who were diagnosed with malignant tumors; 2. Patients are between 18 and 80 years of age are between 18 and 80 years of age. Exclusion Criteria: 1. Participants who were unable or unwilling to provide written informed consent. 2. Participants who were unable to successfully complete the examination and are forced to abort the test in the middle of the test
References
Publications (0)
Data not yet available
No reference posted for this study.